What the science says about your GLP-1 journey.
Everything you need to know about latest research on nutrition, side effects, and supplementation for GLP-1 journey.
Nutrient deficiencies on GLP-1 nearly double between month 6 and 12
A 461,000-patient study found nutrient deficiency on GLP-1 medications climbing from 12.7% at 6 months to 22.4% at one year - here's what to track.
GLP-1 medications linked to 36% lower colorectal cancer risk
An ASCO 2026 analysis of 281,656 people found GLP-1 users were 36% less likely to develop colorectal cancer than aspirin users - but the benefit is not universal.
GLP-1 medications in Parkinson's disease: what the clinical trials actually show
A 2025 systematic review found modest but real motor improvements in some trials, strongest in patients with comorbid diabetes or insulin resistance, with mixed results in major Phase 3 trials.
GLP-1 medications reduce addiction and substance use disorder - VA study
A VA study of 606,434 veterans found GLP-1 medications reduced new substance use disorder risk by 14-25% across opioids, cocaine, nicotine, and alcohol.
Tirzepatide improves sleep quality and fatigue - SURMOUNT-OSA findings
The SURMOUNT-OSA trial found tirzepatide significantly improved sleep disturbance, fatigue, and quality of life in obese patients with sleep apnea at 52 weeks.
GLP-1 medications and mood: what research shows about anxiety, depression, and mental health
New genetic and real-world data suggest GLP-1 medications like semaglutide may reduce anxiety and depression risk - but there is a nuance worth knowing about.
Zenagamtide phase 2 results: 14.6% weight loss and what it means
Novo Nordisk's zenagamtide (amycretin) hit 14.6% weight loss at 36 weeks in Phase 2 with no plateau seen - here is what the ADA 2026 data shows and what it means for GLP-1 users.
GLP-1 and your menstrual cycle: timing matters for weight loss
A new study found GLP-1 medications produce 65% food suppression in the proestrus/estrus phase vs 58% in other phases - and 4.25% more weight loss per cycle phase.
Beyond GLP-1: researchers test a new approach to weight loss
Scientists behind the original GLP-1 drugs are now testing a GIP and glucagon-only molecule that may match semaglutide's weight loss without the nausea - but the evidence is still pre-clinical.
Muscle loss on GLP-1: what the LEAN-PREP trial reveals about prevention
The LEAN-PREP clinical trial is testing whether resistance exercise plus 1.6g/kg/day protein can preserve lean mass on semaglutide and tirzepatide. Here is what the protocol shows.
GLP-1 and gut microbiome: semaglutide reshapes bacteria for better outcomes
Semaglutide treatment reshapes gut bacteria in type 2 diabetes patients - Firmicutes decrease while Bifidobacterium and Bacteroidota increase, with 362 metabolites affected.
Compounded GLP-1 ban: what the FDA proposal means for patients
The FDA proposes to permanently ban compounded semaglutide, tirzepatide, and liraglutide. Public comment closes June 29, 2026. Here is what patients need to know.
Why your body adapts to GLP-1 medications: tolerance and tolerance-breakers
GLP-1 medications reach a plateau around week 52-68 when compensatory hunger mechanisms overcome drug effects. Strategies to maintain efficacy include dose escalation and dietary cycling.
New obesity drug burns fat and preserves muscle - Karolinska study
A Karolinska Institutet study published in Cell found a new β2 agonist tablet burns fat by activating muscle metabolism without suppressing appetite or causing muscle loss.
Liraglutide protects dopamine neurons in diabetic Parkinson's via TNF/necroptosis pathway
A 2025 Frontiers in Neuroscience study shows liraglutide protects dopaminergic neurons in a diabetic Parkinson's mouse model by blocking the TNF-alpha/RIPK3/MLKL necroptosis pathway.
GLP-1 medications and fatty liver disease: ESSENCE trial findings
Semaglutide received FDA approval for MASH in August 2025 with ESSENCE trial showing 62.9% achieved MASH resolution without fibrosis worsening.
GLP-1 gut microbiome: why some people respond better to GLP-1 drugs
A 2026 review in the Canadian Journal of Physiology finds your gut microbiome may explain why GLP-1 medications like semaglutide work better for some people than others.
GLP-1 linked to 44% lower depression risk in major Swedish study
A 95,490-person Swedish study published in The Lancet Psychiatry found semaglutide reduced depression risk by 44% and anxiety by 38%.
Semaglutide and diabetic retinopathy: what real-world data shows
An OHDSI network study of 810,390 semaglutide users found no elevated risk of diabetic retinopathy or macular edema - reassuring real-world safety data on vision.
GLP-1 drugs and addiction: they stop cravings from forming
GLP-1 medications like semaglutide don't just reduce existing addiction cravings - a major VA study and new research suggest they may prevent new addictions from forming entirely.
Semaglutide and kidney disease: what the FLOW trial shows
The FLOW trial found semaglutide cut major kidney events by 24% and all-cause mortality by 20% in people with type 2 diabetes and chronic kidney disease. Here is what the data means.
Duodenal mucosal resurfacing: preventing weight regain after stopping GLP-1
The REMAIN-1 trial found duodenal mucosal resurfacing after tirzepatide discontinuation kept weight stable, with only 7 lbs regain vs 14 lbs in controls at 6 months.
Pemvidutide MASH trial: liver fibrosis improvement with near-zero dropouts in IMPACT Phase 2b
Altimmune's GLP-1/glucagon dual agonist delivered significant liver fibrosis improvement and MASH resolution in Phase 2b with an exceptionally low dropout rate, setting up Phase 3.
Semaglutide and Alzheimer's: what the EVOKE trial failure actually means
Oral semaglutide showed no benefit in the EVOKE Alzheimer's trials. But researchers argue it may still work as prevention - and here is the evidence behind that claim.
Oral GLP-1 drugs penetrate the brain to suppress cravings
A May 2026 NIH-funded Nature study found oral small-molecule GLP-1 drugs like Foundayo activate deep brain reward circuits, reducing pleasure-driven eating and potentially addiction cravings.
What happens to your gut bacteria when you stop GLP-1 medications
When you discontinue semaglutide or tirzepatide, the beneficial microbiota shifts reverse - Firmicutes return to obese-state levels within weeks to months.
Solutions for post-GLP-1 weight regain: what the research shows
70% of GLP-1 users quit within a year and most regain all lost weight within 18 months. New research from DDW 2026 points to emerging strategies that may change that.
Amycretin phase 2 in type 2 diabetes: 14.5% weight loss with no plateau at 36 weeks
Novo Nordisk's GLP-1/amylin dual agonist produced up to 14.5% weight loss and HbA1c below 7% in 89% of type 2 diabetes patients at 36 weeks - with weight loss still descending.
Ozempic mouth: what GLP-1 medications do to your dental health
GLP-1 medications like Ozempic and Wegovy can cause dry mouth, enamel erosion, and gum disease through nausea, vomiting, and nutrient gaps. Here is what to watch for.
GLP-1 hair loss: what the latest research shows
Large-scale data on half a million GLP-1 users shows a real but modest increase in hair loss risk. Here is what is driving it and what you can do.
Semaglutide vs tirzepatide: what the 2026 clinical trials actually show
STEP and SURMOUNT trial data compared side by side: what semaglutide and tirzepatide actually produced in controlled studies, and why real-world results often fall short of the headlines.
Foundayo (orforglipron): the new oral GLP-1 pill - what patients need to know
FDA approved Foundayo (orforglipron) in April 2026 - the second oral GLP-1 for weight loss. Here is what it does, how it differs from Wegovy pill, and who it suits.
Medicare GLP-1 coverage 2026: what the $50 bridge program means for you
Medicare's GLP-1 Bridge program launches July 1, 2026, capping Wegovy and Zepbound at $50/month. Here is who qualifies, what is covered, and what the catch is.
Berberine: nature's Ozempic - what the evidence actually shows
Berberine is called nature's Ozempic, but does it actually work like semaglutide? UCLA Health dietitians and clinical trial data give a more honest answer.
What we know about nutrient deficiency on GLP-1 medications right now
New research on GLP-1 medications like Ozempic and Wegovy reveals how nutrient deficiency and muscle loss affect patients. Here's what an ongoing trial is finding.
GLP-1 medications and your gut microbiome: early findings on nutrient absorption
New research suggests GLP-1 drugs may alter gut bacteria, with potential effects on B vitamin and SCFA production - an under-explored nutritional angle.
Fat-soluble vitamins and GLP-1: an overlooked deficiency risk
Emerging research suggests GLP-1 medications may reduce absorption of vitamins A, D, E, and K more than commonly recognized.
The GLP-1 and gut microbiome loop: what it means for your nutrients
New research reveals a two-way street between GLP-1 drugs and gut bacteria - with real implications for vitamin and mineral levels.
Bone health on GLP-1 medications: what the latest research reveals
New studies show semaglutide and tirzepatide may affect bone density. Here's what long-term patients need to know.
The vitaglp trial: can a multivitamin fix GLP-1 nutrient gaps?
A new clinical trial tests whether multivitamins correct micronutrient deficiencies in GLP-1 patients. Here's what it means for you.
The GLP-1 trial midlife women are waiting for: muscle, bone, and estrogen
A new clinical trial is recruiting to study how GLP-1 medications affect muscle and bone in women over 40. Here's what we know now and what you can do today.
GLP-1 medications and thyroid cancer: what the evidence actually shows
America's highest-volume thyroid cancer center found no convincing proof that Ozempic, Wegovy, or Mounjaro cause the common thyroid cancers making up 95% of all diagnoses.
GLP-1 medications and alcohol: your liver is protected but your blood alcohol rises
A Yale study found GLP-1 medications protect the liver from alcohol's toxic metabolite acetaldehyde - but also raise blood alcohol concentrations and slow clearance in people who drink.
Oral semaglutide cuts heart attack risk 14% - SOUL trial findings
The SOUL trial showed oral semaglutide reduced 3-point MACE by 14% in 9,650 high-risk type 2 diabetes patients over 47.5 months - the first evidence an oral GLP-1 matches injectable cardiovascular protection.
Why some people respond better to GLP-1 drugs: the gut microbiome connection
Your gut microbiome may predict how well semaglutide or tirzepatide works for you. New research explains the bacteria-GLP-1 link and what you can do about it.
Orforglipron maintains weight loss after injectable GLP-1 in the ATTAIN-MAINTAIN trial
Eli Lilly's ATTAIN-MAINTAIN trial tests whether the daily orforglipron pill can sustain weight loss achieved on injectable GLP-1 medications - a critical question for insurance coverage.
Semaglutide and PCOS: early findings from the RESTORE fertility trial
A University of Colorado proof-of-concept study found injectable semaglutide may improve ovulation and fertility in women with PCOS when it produces 10% weight loss or more.
Tirzepatide beats semaglutide in SURMOUNT-5 head-to-head trial
SURMOUNT-5 trial data: tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide over 72 weeks - what the numbers mean for you.
GLP-1 medications and dizziness: 500,000-patient study reveals 4x vertigo risk
A nearly 500,000-patient real-world cohort found semaglutide users show 4.0-4.95x elevated vestibular disorder risk, with dizziness, vertigo, and tinnitus significantly underreported as GLP-1 side effects.
How GLP-1 medications reduce addiction and cravings: the neuroscience
GLP-1 medications like Ozempic and semaglutide are showing striking effects on alcohol, nicotine, and opioid cravings. Here is what the neuroscience actually explains.
Semaglutide and tirzepatide cardiovascular outcomes: real-world data
Nature Medicine study of 800,000+ patients shows semaglutide and tirzepatide provide comparable heart protection in real-world clinical practice.
GLP-1 side effects: what the science actually shows
A comprehensive review of GLP-1 side effects from the Journal of Clinical Investigation: nausea rates, thyroid risk, retinopathy, psychiatric safety, and more.
GLP-1 medicines cut fat while preserving muscle function
Cell Reports Medicine study: tirzepatide drove 73% of weight loss from fat in mice, and human participants showed no decline in leg strength after 12 weeks on semaglutide.
Semaglutide in pregnancy: first-trimester exposure risk and the counseling gap
A 2025 Obstetric Medicine review finds a critical gap: women on GLP-1 medications are not being told the drug may reduce oral contraceptive absorption and must be stopped before conception.
How semaglutide disrupts gastric electrical signals - the gastroparesis link
A 2026 pilot study found semaglutide reduced gastric muscle contractility and triggered irregular electrical activity in 63% of patients - providing a key mechanism for GI side effects and gastroparesis risk.
What vitamins are you deficient in on GLP-1 medications?
GLP-1 medications like Ozempic and Wegovy shrink your appetite - but research shows they may also leave critical nutrient gaps that most patients never hear about.
GLP-1 fracture risk in women: what the SELECT trial bone health review found
A 2025 Osteoporosis International review of the SELECT trial found semaglutide linked to hip and pelvic fractures in females at rates 5x higher than controls, with bone effects resembling calorie restriction.
GLP-1 medications linked to lower breast cancer incidence - Penn study
A Penn Medicine study of 111,646 women found GLP-1 users had 30-35% lower odds of breast cancer - the largest US health system study on this link to date.
The GLP-1 stigma paradox: losing weight may not end the judgment
A Rice University study in the International Journal of Obesity found GLP-1 medication users face more social stigma than people who lost weight through diet alone - or didn't lose weight at all.
Semaglutide heart benefits independent of weight loss: SELECT trial findings
The Lancet SELECT trial prespecified analysis found semaglutide reduced major cardiac events by 20% across all adiposity levels - only one-third of the benefit was explained by weight loss.
FDA approves oral Wegovy pill: first oral GLP-1 for weight loss
FDA approved semaglutide 25 mg tablets (Wegovy pill) for weight loss in December 2025 - what the OASIS 4 trial showed and what it means for patients.
Retatrutide TRIUMPH-1 results: the triple-G drug that beats Wegovy and Zepbound
Eli Lilly's retatrutide delivered 28.3% average weight loss in Phase 3 TRIUMPH-1 - more than any approved GLP-1 drug. Here is what the data actually shows.
What happens when you stop taking Ozempic or Wegovy?
Stopping semaglutide or tirzepatide leads to rapid weight regain for most people - research shows up to two-thirds of lost weight returns within a year. Here is what to do about it.
GLP-1 drugs for addiction: who is running trials in 2026 and what to expect
At least 10 clinical trials are testing GLP-1 medications for alcohol, opioid, nicotine, and stimulant use disorders in 2026 - here is who is running them and when results are expected.
GLP-1 medications and heart failure: 22,000-patient systematic review finds clear benefit in HFpEF
A 2025 meta-analysis of 16 trials and 22,000 patients finds GLP-1 medications significantly reduce hospitalisations and improve quality of life in heart failure with preserved ejection fraction.
VK2735 oral Phase 2: 12.2% weight loss at 13 weeks with no plateau
Viking Therapeutics' oral VK2735 (GLP-1/GIP dual agonist) achieved 12.2% weight loss at 13 weeks in the VENTURE trial with 97% of participants losing 5% or more - and the weight curve still descending.
What's ahead for GLP-1 medications in 2026
From oral pills to Medicare access and next-gen triple agonists, 2026 is shaping up as the biggest year yet for GLP-1 medications like Ozempic, Wegovy, and tirzepatide.
Semaglutide for fatty liver disease: what the ESSENCE trial and FDA approval mean
The FDA approved Wegovy for MASH with liver fibrosis in 2025. The ESSENCE trial showed 63% MASH resolution. Here is what GLP-1 users with fatty liver need to know.
GLP-1 bone density decline: 255 patients, 34 months, real-world data
A Weill Cornell real-world study of 255 patients over 34 months found bone mineral density declined across all sites, with 13% developing new fractures and diabetics at 3x higher risk.
How many people qualify for GLP-1 medications worldwide?
A Lancet study of 810,635 adults across 99 countries found 27% of global adults qualify for GLP-1 therapy - but access remains deeply unequal.
GLP-1 drugs as addiction treatment: the substance-by-substance evidence
A BMJ study of 606,434 veterans found semaglutide cut opioid use disorder risk by 25% and drug-related deaths by 50%. Here is what the evidence shows for each addictive substance.
GLP-1 medications in gestational diabetes: safety review of 8 clinical trials
A 2025 Medicine systematic review of 8 trials finds no increase in major congenital malformations or perinatal mortality, with better glucose control than comparators.
Muscle loss on GLP-1 medications: what the research actually shows
Losing muscle on Ozempic or Wegovy? New data from Cell Reports Medicine shows fat - not muscle - accounts for most GLP-1 weight loss, but the full picture is more nuanced.
GLP-1 medications and gallbladder disease: 1,829 cases in FAERS analysis
A FAERS pharmacovigilance analysis of 1,829 adverse event reports confirms a positive signal for GLP-1-induced cholecystitis across all agents, with liraglutide and semaglutide showing the strongest association.
GLP-1 medications in breast cancer patients: what oncologists need to know
A narrative review found GLP-1 receptor agonists are safe in breast cancer survivors with no increased recurrence risk and lower all-cause mortality.
Semaglutide and biological aging: what the epigenetic clock data shows
A 32-week RCT found semaglutide reduced biological age by 3.1-4.9 years on epigenetic clock measures - but the study was in HIV patients and the results are preliminary.
Why GLP-1 medications cause gallbladder problems: the bile acid science explained
A 2025 review identifies three molecular mechanisms behind GLP-1 gallbladder disease risk - CCK suppression, FXR/TGR5 pathway disruption, and altered bile acid composition - and who is most vulnerable.
What GLP-1 users need to know about muscle loss and protein intake
New ongoing research tracks muscle loss on GLP-1 medications and how protein intake can preserve strength. Here is what we know so far.
No articles in this category yet.